In a report released yesterday, Marie Thibault from BTIG maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The company’s shares closed last Wednesday at $116.07, close to its 52-week high of $123.27.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 41.0% and a 53.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Boston Scientific.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $121.79 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $123.27 and a one-year low of $70.92. Currently, Edwards Lifesciences has an average volume of 2.06M.
Based on the recent corporate insider activity of 127 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in August 2021, Catherine Szyman, the CVP, Critical Care of EW sold 15,000 shares for a total of $1,702,800.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
Read More on EW:
- Exscientia Plc (EXAI) Gets a Buy Rating from Barclays
- Olaplex Holdings (OLPX) Gets a Hold Rating from Barclays
- Kimberly Clark (KMB) was Downgraded to a Hold Rating at Barclays
- William Blair Maintains a Buy Rating on Aspen Technology (AZPN)
- Is Micron Stock a Buy Right Now? This Is What You Need to Know
